Our Oral GLP-1 Programme Proprietary delivery technology microencapsulates peptides for oral delivery to a specific area of the gut, using pH sensitive release mechanism to deliver the drug to its intended site of action Potential to overcome oral delivery challenges of peptide-based biologicals Effectiveness of the technology has already been validated via the commercialisation of encapsulated oral probiotics and nutraceuticals by AnaBio Technologies, our collaborative partner Proof of Concept Trial Proof of Concept Trial Progressing towards proof of concept trial to determine that a GLP-1R agonist can be successfully delivered orally in humans expected to commence H2 2026, with the potential for partnering on positive data
Terminology used to develop this topic mainly included HIV, Glutathione, N-acetylcysteine, antioxidants, cell-mediated immunity, HIV-associated neurodegenerative diseases, interleukins, free radicals, and T cells
- Vin ung trng da Now Glutathione 500mg gii c gan, hi phc chc nng gan trong x gan, suy gan, bo v t bo gan trong vim gan nhim c, vim gan siu virus, c ch s sao chp virus HAV, HBV, HCV
The confusion typically comes from the same places as any peptide calculation mg-to-mcg mix-ups, and unit-vs-mL confusion on the syringe
When stomach contents remain in the stomach for longer periods, there is greater opportunity for acidic material to reflux back into the oesophagus, particularly in individuals who already have a predisposition to reflux disease
Sources Eli Lilly press release TRIUMPH-1 Phase 3 topline results, May 21, 2026 Eli Lilly press release TRIUMPH-4 Phase 3 trial results, December 2025 Eli Lilly press release TRANSCEND-T2D-1 topline results, March 19, 2026 Bajaj HS et al
